Biovica announced that the Center for Medicare & Medicaid Services (CMS) after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U. The comments CMS received included detailed information as to how these tests are similar enough to make the crosswalk. Utilizing the Crosswalk pricing method, DiviTum TKa will be priced at USD322 per test effective from January 1st, 2024.

This CMS decision allows Biovica to bypass the previously announced pathway via the so-called Gapfill process, which would have entailed an additional year of engagement to establish pricing for DiviTum TKa. The decision means there is a high probability to deliver in line with, or even above, the average price of $400 per test that has previously been communicated, as established agreements with private actors are significantly higher in price.